A female user with alopecia is researching peptide usage, specifically ghk-cu, for hair loss. Other users shared mixed experiences with copper treatments, noting some success with topical application.
The conversation discusses the lack of public information on the chemical structure of PP405, a hair loss treatment, and the challenges of synthesizing it without a patent. It also explores a patent related to hydrogen-based topical formulations for reducing oxidative stress and inflammation.
Users are concerned about inconsistencies in the packaging and form of a Minoxidil, finasteride, and Biotin blend from LockLab.co, with some receiving capsules and others tablets. Despite reassurances from customer service about changes due to maintenance, users remain skeptical about the product's authenticity and effectiveness.
PP405 shows promise for hair growth but may need continuous use like Minoxidil. Current treatments include Minoxidil, finasteride, and dutasteride, with skepticism about a true cure due to financial interests.
The conversation is about the delay in receiving updates on the HMI-115 phase 1 trial for hair loss. No specific treatments are mentioned in the conversation.
RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.
Verteporfin and FAK inhibitors being looked at as potential treatments for hair regeneration, with updates on the unofficial off-label human trial being discussed.
The conversation is about seeking updates on new hair loss treatments, specifically mentioning scube3 and GT20029, with one person mentioning HMI_115 as showing promising results.